Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10637123 | 0.85 | KDM4E (0.52) | SMN1; SMN2CYP1A2CYP2C19CYP2A6RAB9A | |
| SCHEMBL7983660 | 0.85 | ALDH1A1 (0.53) | SMN1; SMN2GAAL3MBTL1TDP1CYP2A6 | |
| SCHEMBL28990411 | 0.82 | CYP2A6 (0.47) | SMN1; SMN2CYP2C19TDP1CYP2A6RAB9A | |
| SCHEMBL27757114 | 0.81 | OPRL1 (0.47) | SMN1; SMN2GAACYP2A6RAB9AALDH1A1 | |
| SCHEMBL7831579 | 0.80 | CNR2 (0.48) | SMN1; SMN2CYP1A2CYP2C19RAB9AKDM4E | |
| SCHEMBL7833535 | 0.80 | CNR2 (0.48) | SMN1; SMN2CYP1A2CYP2C19RAB9AKDM4E | |
| SCHEMBL11451549 | 0.80 | CYP2A6 (0.37) | L3MBTL1TDP1CYP2A6RAB9AKDM4E | |
| SCHEMBL3739311 | 0.80 | TDP1 (0.53) | CYP2C19GAAL3MBTL1TDP1CYP2A6 | |
| SCHEMBL31426339 | 0.80 | PLG (0.46) | SMN1; SMN2L3MBTL1KDM4EHSD17B10EGFR | |
| SCHEMBL29491509 | 0.80 | ACACB (0.41) | SMN1; SMN2CYP1A2CYP2C19L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2022268066-A1 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20220313826-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| CN-111116576-A | Quinolizinone compound and preparation method thereof | 北京师范大学 | 2020-05-08 | — | — | CN | disclosed |
| CN-109641874-A | C for target protein degradation3The glutarimide degron body of carbon connection | C4医药公司 | 2019-04-16 | — | — | CN | disclosed |
| EP-3455218-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2017197046-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197046-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| CN-100467598-C | Fungal cell wall synthetic genes | EISAI CO LTD (JP) | 2009-03-11 | — | — | CN | disclosed |
| CN-100467597-C | Fungal cell wall synthetic genes | EISAI CO LTD (JP) | 2009-03-11 | — | — | CN | disclosed |
| CN-101285061-A | Fungal cell wall synthetic genes | EISAI R&D MAN CO LTD (JP) | 2008-10-15 | — | — | CN | disclosed |
| CN-1873002-A | Fungal cell wall synthesis gene | EISAI CO LTD (JP) | 2006-12-06 | — | — | CN | disclosed |
| CN-1873003-A | Fungal cell wall synthesis gene | EISAI CO LTD (JP) | 2006-12-06 | — | — | CN | disclosed |
| CN-1249227-C | Fungal cell wall synthetic genes | EISAI CO LTD (JP) | 2006-04-05 | — | — | CN | disclosed |
| CN-1449443-A | Fungal cell wall synthetic genes | EISAI CO LTD (JP) | 2003-10-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | SMN1; SMN2 3245/4885CYP1A2 3960/4885CYP2C19 4586/4885 |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | SMN1; SMN2 4153/4885CYP1A2 3455/4885CYP2C19 4255/4885 |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | SMN1; SMN2 4153/4885CYP1A2 3455/4885CYP2C19 4255/4885 |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | SMN1; SMN2 4153/4885CYP1A2 3455/4885CYP2C19 4255/4885 |
| US-20220313826-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | SMN1; SMN2 4153/4885CYP1A2 3455/4885CYP2C19 4255/4885 |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | SMN1; SMN2 4153/4885CYP1A2 3455/4885CYP2C19 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.